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Aging is a complex process accompanied by a decreased
capacity of cells to cope with random damages induced by reac-
tive oxygen species, the natural by-products of energy metabo-
lism, leading to protein aggregation in various components of
the cell. Chaperones are important players in the aging process
as they prevent proteinmisfolding and aggregation. Small chap-
erones, such as small heat shock proteins, are involved in the
refolding and/or disposal of protein aggregates, a feature of
many age-associated diseases. In Drosophila melanogaster,
mitochondrial Hsp22 (DmHsp22), is localized in the mitochon-
drial matrix and is preferentially up-regulated during aging. Its
overexpression results in an extension of life span (>30%) (Mor-
row, G., Samson, M., Michaud, S., and Tanguay, R. M. (2004)
FASEB J. 18, 598–599 and Morrow, G., Battistini, S., Zhang, P.,
and Tanguay, R. M. (2004) J. Biol. Chem. 279, 43382–43385).
Long lived flies expressing Hsp22 also have an increased resist-
ance to oxidative stress andmaintain locomotor activity longer.
In the present study, the cross-species effects of Hsp22 expres-
sion were tested. DmHsp22 was found to be functionally active
in human cells. It extended the life span of normal fibroblasts,
slowing the aging process as evidenced by a lower level of the
senescence associated -galactosidase.DmHsp22 expression in
human cancer cells increased theirmalignant properties includ-
ing anchorage-independent growth, tumor formation in nude
mice, and resistance to a variety of anticancer drugs. We report
that the DmHsp22 interacts and inactivates wild type tumor
suppressor protein p53, which may be one possible way of its
functioning in human cells.
The small heat shock proteins (sHsps)5 are members of a
superfamily of proteins that share a highly conserved 80-
amino acid -crystallin domain in their C-terminal domain. Like
other heat shock proteins, sHsps exhibit a highly dynamic
structure forming both homo- and hetero-oligomeric com-
plexes, possess chaperone-like activity, and are involved in a
plethora of functions ranging from protein folding to apoptosis
and stress resistance. In human cells, there are 11 members in
the family: Hsp27 (HspB1,Hsp25),myotonic dystrophy protein
kinase-binding protein (HspB2), HspB3, A-crystallin
(HspB4), B-crystallin (HspB5), Hsp20 (p20, HspB6), cardio-
vascular heat shock protein (HspB7), Hsp22 (Hsp22/HspB8/
H11) and HspB9 (1–4). Although very similar in structure, the
different sHsps show specificity in terms of response to stress,
in tissue, and developmental expression, suggesting that they
have different functions. sHsps have been reported to act at
various steps of the apoptotic process, but the structure/func-
tions of these small proteins remain poorly understood. The
tissue and developmental stage-specific pattern of sHsp expres-
sion has suggested their role in specific tissue functions, main-
tenance, and modulation of tissue integrity, dynamics of struc-
tural elements, spatial organization, and apoptosis that play an
important role in development, control of cell proliferation,
and carcinogenesis (1, 5–7). Specific point mutations in a num-
ber of small Hsps can destabilize the protein structure and have
been reported to be associated with a number of neurodegen-
erative disorders such as distal hereditary motor neuropathy
and/or Charcot-Marie-Tooth neuromuscular diseases (2, 3, 8).
Interestingly, K141N and K141Emutations that induced struc-
tural destabilization of the protein also reduced its chaperone
activity, enhanced the formation of homo- and heterodimers,
and increased the formation of intracellular aggregates (9–13).
Indeed, wild type Hsp22 was shown to block the accumulation
of polyglutamine protein (Htt43Q) in inclusion bodies, suggest-
ing its molecular chaperone function keeps Htt43Q in a soluble
and rapidly degradable state.
In Drosophila melanogaster, in which the sHsps were first
reported, there are fourmainmembers that showdistinct intra-
cellular localization (14), One of these, D. melanogaster Hsp22
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(DmHsp22) localizes distinctly in the mitochondrial matrix
(15) and shows heat and oxidative stress-inducible features and
chaperone-like activity (16). DmHsp22 is up-regulated during
Drosophila aging (17). Flies selected for increased longevity
were also found to display an earlier onset of Hsp22 and Hsp23
transcription (18). Ubiquitous or targeted expression of Hsp22
within motor neurons resulted in a 30% increase in Drosophila
mean life span and beneficial effects such as, increased locomo-
tor activity, resistance to oxidative injuries, and thermal stress
(19). On the other hand, flies compromised for Hsp22 expres-
sion showed a 40% decrease in life span and displayed a 30%
decrease in locomotor activity and higher sensitivity to mild
stress (20). Histone deacetylase inhibitor trichostatin A was
shown to promote hsp22 gene transcription and extend the
life span of D. melanogaster (21, 22). The selected long lived
Drosophila lines showed higher level of Hsp22 expression,
respondedmore rapidly to heat, andweremore tolerant to high
temperature (15, 18, 22).
In the present study, we investigated the cross-species effects
of Hsp22.We report that theDmHsp22 is functionally active in
human cells. Indeed, the expression of DmHsp22 extends the
life span of normal human fibroblasts and increased the malig-
nant properties of human cancer cells. Moreover, DmHsp22-
expressing cancer cells formed aggressive tumors and acquired
a drug-resistant phenotype. We further report that DmHsp22
interacts with and inactivate wild type tumor suppressor p53 in
human cancer cells, suggesting that this interaction may repre-
sent one of the mechanisms of its proproliferative function.
MATERIALS ANDMETHODS
Cell Culture—Human normal fibroblasts (TIG-1) and can-
cerous cells, osteosarcoma (U2OS), breast carcinoma (MCF7),
and lung carcinoma (A549), were propagated in low glucose
Dulbecco’s modified Eagle’s minimal essential medium supple-
mented with 10% fetal bovine serum and 1% antibiotics-anti-
mycotics (Sigma). DmHsp22-overexpressing cells were gener-
ated by retrovirus-driven expression. The cDNA encoding
D. melanogasterHsp22 protein was cloned into theHindIII site
of the vector CX4neo (pCX4neo, provided by Dr. Akagi, Osaka,
Japan). For production of retroviruses, Plat-E, an ecotropic
murine leukemia virus-packaging cell line was transfected with
the pVPack-GP (expressing gag and pol) and pVPack VSVG
(expressing env) vectors (Stratagene) alongwith either pCXneo
retroviral vector or pCX4neo/DmHsp22 using FuGENE6
(Roche Applied Science). After 48 h, culture supernatants were
collected and filtered through 0.45-m filters. The filtered
supernatants (viral stock) were used for cell infection without
freeze thawing. Cells (2  105/well in 6-well dishes) were
treatedwith 8g/ml polybrene at 37 °C for 1 h, after which they
were incubated with 200–300 l of filtered viral stock for 1 h
followed by addition of 2 ml of Dulbecco’s modified Eagle’s
minimal essential medium and continued incubation at 37 °C
for further 48 h. The infected cells were selected in medium
containing G418 (100–200 g/ml for normal and 500 g/ml
for cancer cells) until stable expressing cell lines were obtained.
The stably infected cells lines were examined for expression of
DmHsp22 by Western blotting and immunostaining with spe-
cific antibody (15) and were maintained in 100 g/ml G418-
supplemented medium. Normal control and DmHsp22-ex-
pressing cells were serially passaged in parallel. The passage
ratio was kept at 1:16 for young cultures and was decreased to
1:8 or 1:4 as they aged. Serial passagingwas continued until cells
stopped dividing and entered senescence. The nondividing
senescent cells were maintained for4 weeks before termina-
tion of the experiment.
Western Blotting and Immunoprecipitation—Control and
DmHsp22-expressing cells were trypsinized and solubilized in
Nonidet P-40 lysis buffer. The lysates were centrifuged at
13,000 rpm for 10min at 4 °C to remove cell debris. The protein
concentrations were determined by Bradford protein assay fol-
lowing the manufacturer’s instructions. Lysates containing
20–30 g protein were boiled in SDS sample buffer for 5 min,
subjected to SDS-PAGE under reducing conditions and then
transferred onto Immobilon-P membranes (Millipore) using a
semidry transfer apparatus (ATTO). After washing with Tris-
buffered saline-Triton X-100, the membrane was incubated
with the first and second (horseradish peroxidase-conjugated)
antibodies as indicated. The membrane was washed thrice in
Tris-buffered saline-Triton X-100 and once in Tris-buffered
saline, then subjected to an enhanced chemiluminescence-
mediated visualization (Amersham Biosciences) using an
Lumino Image Analyzer equipped with a CCD camera
(LAS3000-mini, FujiFilm). Mitochondrial fractions were pre-
pared using the Qproteome mitochondria isolation kit
(Qiagen) following themanufacturer’s instructions.Washed cells
were suspended with lysis buffer for disrupting the plasma
membrane.After incubation for 10min, lysatewere centrifuged
at 1,000  g for 10 min at 4 °C, and then the supernatant was
harvested as a cytosolic fraction. Pellet containing nuclei, cell
debris, and unbroken cells was resuspended with ice-cold dis-
ruption buffer. Resuspended pellet was centrifuged at 1,000 g
for 10 min at 4 °C, and then the supernatant was harvested as a
microsomal fraction. The resulting pellet was centrifuged at
8,000 g for 10 min at 4 °C for mitochondrial fraction by den-
sity gradient purification. After centrifugation, the band toward
the bottom of the tube was harvested as a mitochondrial frac-
tion. For in vivo coimmunoprecipitation, cell lysates (300 g
protein) in 300l ofNonidet P-40 lysis buffer were incubated at
4 °C for 1–2 h with anti-DmHsp22 antibody. Immunocom-
plexes were separated by incubation with Protein A/G-Sepha-
rose, and Western blotting was performed with the indicated
antibodies using the procedure described above.
Immunostaining—Cells grown on coverslips were fixed in
methanol:acetone (1:1), permeabilized with 0.2% Triton X-100
and blocked with 5% bovine serum albumin in phosphate-buff-
ered saline (PBS). Cells were probed with primary antibody (as
indicated) for 1–2 h. Staining was visualized by Alexa Fluor 594
(rabbit)-conjugated secondary antibody. The cells were exam-
ined on a Carl Zeiss microscope attached with either a Photo-
metrics Synsys monochrome CCD (charge-coupled device) or
an AxioCam HRC color camera (Zeiss).
Senescence-associated -Galactosidase Assay—Senescent
cells were detected using the standard protocol for senescence-
associated -galactosidase staining assay. In brief, cells were
washed with PBS, fixed with 2% formaldehyde/0.2% glutaralde-
hyde in PBS for 10min, andwashed againwith PBS, followed by
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an overnight incubation in staining solution (citric acid/phos-
phate buffer, pH 6.0, 5mMK3Fe (CN)6, 5mMK4Fe(CN)6, 2mM
MgCl2, 150mMNaCl, supplementedwith 1mg/ml of 5-bromo-
4-chloro-3-indolyl--D-galactopyranoside (X-gal) at 37 °C.
Stained cells were observed under the microscope and pho-
todocumented with a NIKON camera.
Cell Transformation Assays—Cell transformation assay was
performed by using the Cell Transformation Detection kit
(CHEMICON) following the manufacturer’s instructions. Base
agar solution (0.8% agar in culturemedia) and top agar solution
(0.4% agar in culturemedia) were prepared and preincubated at
37 °C. Plates (24-well) were coated with base agar solution and
stored at 4 °C until use. Prior to use, plates were warmed up for
5min by placing at 37 °C incubator. An equal number ofMCF7,
U2OS, A549, and each Hsp22-expressing cells (1250 cells/well
of 24-well plate) wasmixed with top agar solution. Themixture
of cells and top agar solution was then placed on the top of base
agar layer. Cells were fed with cell culture media twice a week
and incubated at 37 °C with 5% CO2. On day 28, colonies were
stained with cell stain solution. Colony-forming activity is
expressed as the mean number of colonies in five fields from
three independent experiments.
Chemotaxis Assay—Chemotaxis assays were performed on
control and DmHsp22-transduced cells. Cells at 60–70% con-
fluency were washed with cold PBS, trypsinized, and resus-
pended in Dulbecco’s modified Eagle’s minimal essential
medium supplemented with 0.5% bovine serum albumin
(Sigma) at 2 105 cells/ml. 2 104 cells were plated in Tran-
swell inserts (12 mm-pore, Costar), and the invasion assay
was performed following the manufacturer’s instructions.
Fibronectin from human plasma (Sigma) was used as chemoat-
tractant. Cells that moved through the transwell were fixed
with 4% formaldehyde in PBS and
stained with crystal violet (0.2% in
PBS).
Nude Mice Assay—Balb/c nude
mice (4 weeks old, female) were
bought from Nihon Clea. Control
and DmHsp22-transduced cells (1
106 suspended in 0.3 ml of growth
medium) were injected subcutane-
ously into the flank of nude mice
(two sites per mouse). Tumor for-
mation was monitored for the next
month. The assay was regarded as
positive if tumors appeared and
grew progressively.
In Vitro Cell Invasion Assay—
Control and DmHsp22-expressing
cells were grown in the monolayer.
A wound was made in the mono-
layer of cells by completely scratch-
ing the cells in a line with a pipette
tip. Cells were washed a few times
with PBS to remove cell debris and
fed with fresh medium. The time of
scratching woundwas designated as
time 0. Cells were allowed to prolif-
erate and migrate into the wound during the next 48 h. Migra-
tion of cells into the wound was recorded under a phase con-
trast microscope with a 10 phase objective.
Cell Viability and Drug Resistance Assay—Equal number of
control andDmHsp22-expressingMCF7 cells were seeded on a
96-well plate in a medium containing 5% FBS at 1  104 cells
per well. When the cells reached subconfluence, cells were
treatedwith campothecin, nocodazol, etoposide, or taxol at dif-
ferent doses. After a 48-h incubation, cultured media contain-
ing drug was removed, and 5% alamarBlue in culturemedia was
added to culture wells. After a 4-h incubation at 37 °C, culture
plates were read on a microplate reader at 595 nm. All assays
were performed in triplicate. The number of living cells was
calculated relative to the cells with nontreatment of drug, cul-
tured, and treated with 5% alamarBlue in culture media under
the same conditions, as were the experimental groups.
Statistical Analysis—The data obtained by three or more
independent experiments were analyzed by Mann-Whitney
test (nonparametric rank sum test) using StatView software
(Abacus Concepts, Inc., Berkeley, CA). Differences were con-
sidered significant when p 0.05.
RESULTS ANDDISCUSSION
Drosophilamitochondrial Hsp22was cloned into a retroviral
expression vector as described in “Material and Methods” and
was expressed in normal human fibroblasts (TIG-1). The cells
were infected with vector (control) or DmHsp22-expressing
retroviral vector at population doubling (PD) 24; the expression
ofDmHsp22 was confirmed byWestern blotting and immuno-
staining assays with an antibody that specifically detected
DmHsp22 (Fig. 1, A and B; data not shown). Of note, no cross-
reactivity of the antibody was observed with any of the other
FIGURE 1.Normal human fibroblasts expressingDmHsp22underwent extendedPDs in culture.Whereas
control cells divided for 58 PDs, theDmHsp22-expressing cells underwent 84 PDs. Expression ofDmHsp22was
detected byWestern blotting (A) and immunostaining (B) using anti-DmHsp22 antibody. In vitro serial passag-
ing of the control and DmHsp22-infected cells was performed in parallel, and the senescent cells were main-
tained for at least 3 weeks (C). Cells were stained for senescence-associated -galactosidase; representative
images at45 PD are shown (D).
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human proteins. Control and DmHsp22-expressing cells were
serially passaged. Whereas control cells entered senescence at
45 PD, as marked by their morphology and slow growth, the
DmHsp22-expressing cells showed younger morphology and
continued dividing until65 PD (Fig. 1C). Control cells under-
went 58 PD, whereas DmHsp22-expressing cells divided for 84
PD. Upon examination of senescence-specific -galactosidase
staining in control and DmHsp22 cells at parallel PD (48–50
PD), we found significant lower level of -galactosidase expres-
sion in DmHsp22-expressing cells (Fig. 1D), suggesting that
these cells have extended life span and slowed the rate of the
aging process. Of note, the parallel experiments in which the
mitochondrial chaperone mor-
talin/mtHsp70 was infected into
TIG-1 cells gave a similar life span
extension as reported earlier (23,
24).
Up-regulationofmortalinhasbeen
reported in a variety of tumors, and it
was shown to contribute to human
carcinogenesis (25–27). Based on our
above findings that the small mito-
chondrial Hsp22 ofD. melanogaster
caused life span extension of human
fibroblasts, we next investigated the
effects of DmHsp22 expression on
human cancer cells. Human breast
cancer cells (MCF7) infected with
DmHsp22 virus were examined for
their malignant properties in com-
parison to the control cells (Fig. 2).
Cell transformation, cell migration,
and nude mice assays in control
(vector-transfected) andDmHsp22-
expressing cells (Fig. 2, A and B)
revealed that the expression of
DmHsp22 caused malignant trans-
formation of breast cancer cells.
Control cells neither showedmigra-
tion in chemotaxis assay, nor
anchorage-independent growth (col-
ony formation in soft agar), and
nor formed tumors in nude mice
tumor. In contrast, DmHsp22-
expressing cells showed migration
in the chemotaxis assay, anchor-
age-independent growth, and formed
tumors in nude mice (Fig. 2B). Sim-
ilar to the MCF7 cells, human lung
carcinoma (A549) and osteosar-
coma (U2OS) cells showed en-
hanced malignant properties as a
consequence to the expression
of DmHsp22. Anchorage-indepen-
dent growth was increased in both
cell types as a consequence of
DmHsp22 expression (Fig. 2C). In
wound scratch/cell invasion as-
says, DmHsp22-expressing cells showed enhanced motility
(Fig. 2D). These data demonstrated that the DmHsp22 is func-
tional in human cells and has effects that match with the over-
expression of mortalin.
Drug resistance is a common feature of aggressive cancers.
In particular, estrogen receptor-positive breast cancers that
are treated with endocrine therapy meet only a limited suc-
cess rate because of the drug-resistant phenomenon. For
example, a large number of originally tamoxifen-sensitive
tumors develop resistance after several months of treatment
while still expressing the estrogen receptor (28). Mecha-
nism(s) of estrogen response plays a critical role in the etiol-
FIGURE 2.DmHsp22 expression in human breast (MCF7) and lung (A549) cancer cells withwild type p53
caused their malignant transformation. Expression of DmHsp22 was detected by Western blotting with
anti-Hsp22 antibody (A). Vector and DmHsp22-infected cells were assayed for invasion by chemotaxis assay
(B, left panel), colony forming capacity (B, middle panel), and tumor formation in nude mice (B, right panel).
Colony-forming efficiency of the vector and DmHsp22-expressing A549 and U2OS (osteosarcoma) cells is
shown in C. Invasive capacity of A549 cells as investigated by wound-scratch assay is shown in D. Differences
were considered statistically significant when p 0.05.
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ogy, progression, drug resistance, and treatment of breast
cancers and are not clearly understood. Furthermore, cad-
mium (metalloestrogen and environmental pollutant) that
has been implicated in breast cancer resulted in an induction
of human HspB8, suggesting that this sHsp may mediate
estrogenic response in estrogen receptor-positive breast
cancer cells that often develop drug resistance (29–31). In
view of these reports and our findings described above, we
next examined whether the mitochondrial DmHsp22, be-
sides increasing the malignant properties of cancer cells,
could make them resistant to drugs. The response to the four
commonly used anti-cancer drugs was examined by cell via-
bility assays. As shown in Fig. 3, the DmHsp22-expressing
cells showed resistance to killing by each of the four drugs
tested. Small Hsps have also been shown to form small
molecular mass oligomers and interacts with biological
membranes and proteins (3). Therefore, it is possible that
such interactions of Hsp22 with membrane elements may
regulate the drug intake and metabolism and hence modu-
late the signal transduction that induces growth arrest or
killing.
The tumor suppressor p53 pathway has a definitive role in
cellular senescence and is inactivated in a large variety of
cancers. Mortalin was shown to interact with p53 and inac-
tivates its transcriptional activation function (32–35) that
contributes to its proproliferative impact. To get insights to
the mechanism(s) by which DmHsp22 induced proprolifera-
tive phenotypes in human cells, we examined its effect on the
p53 pathway. We first examined the subcellular localization
of DmHsp22 by cell fractionation and detection with anti-
DmHsp22 antibody. As expected and shown in Fig. 4A,
DmHsp22 was localized predominantly in the mitochondria,
although there was some amount detected in themicrosomal
fraction as well. Immunoprecipitation of DmHsp22 and sub-
sequent detection of p53 in the DmHsp22 immunocomplexes
revealed interactions between the two proteins (Fig. 4B). An
increasing number of recent studies has shown that p53 is local-
ized inmitochondria and contributes to apoptosis independent
to its transcriptional activation function in the nucleus (36–
39). AlthoughMCF7 cells could not be used for this assay due to
extremely low levels of wild type p53 in these cells, we detected
mitochondrial localization of p53 in U2OS cells (Fig. 4C).
We next hypothesized that, similar to mortalin, DmHsp22
may cause functional inactivation of p53 by its cytoplasmic
sequestration (32). We tested this by undertaking double
immunostaining assays for p53 (green) andDmHsp22 (red).We
FIGURE 3. Drug response of vector and DmHsp22-infected cells was
determinedby cell viability assay.DmHsp22-expressing cells showeddrug
resistance. Representative response to camptothecin, nocodazol, etoposide,
and taxol in three independent experiments are shown. Differences were
considered statistically significant when p 0.05.
FIGURE 4. Cellular localization of DmHsp22 and its interaction with p53
protein. Subcellular localization of DmHsp22 in MCF7 cells was determined
by cellular fractionation into cytosolic, microsomal, and mitochondrial frac-
tions and detection of the protein by Western blotting with anti-DmHsp22
antibody. As shown,DmHsp22 localized in themitochondria andmicrosomal
fractions (A). DmHsp22 was immunoprecipitated with anti-Hsp22 antibody,
and the presence of p53 in immunocomplexes was determined by Western
blotting with anti-p53 antibody. p53 was detected in the DmHsp22 com-
plexes (B) in MCF7 cells and also mitochondrial fraction of U2OS cells (C).
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found that, whereas control U2OS cells had 67% of cells show-
ing nuclear p53, DmHsp22-expressing cells showed only 22%
cells with nuclear p53. Furthermore, the intensity of nuclear
p53 staining in DmHsp22-expressing cells was lower as com-
paredwith the control cells (Fig. 5). Furthermore, inDmHsp22-
expressing U2OS cells, we found that there was a significant
decrease in DNA damage-induced activation of p53 pathway.
As shown in Fig. 5A, control cells showed strong nuclear p53
staining subsequent to the treatment with etoposide, whereas
inDmHsp22-expressing cells, the nuclear p53 was significantly
abrogated and was particularly noticeable in cells that
expressed high levels of DmHsp22, suggesting that the
DmHsp22 inactivated tumor suppressor p53 by interacting
with and inhibiting its nuclear transport (Fig. 5,A andB).Quan-
titation of number of cells with very strong nuclear p53 staining
subsequent to etoposide treatment in control and DmHsp22-
expressing cells revealed that the inactivation of p53 by
DmHsp22 in U2OS, A549, andMCF7 cells was statistically sig-
nificant (Fig. 5B and data not shown). We further examined if
the similar inactivation of p53 byDmHsp22 occurred in normal
human cells and had resulted in their lifespan extension as
shown in Fig. 1C. Immunostaining of p53 in control and
DmHsp22-expressing TIG-1, A549, MCF7, and U2OS cells
revealed that in each case DmHsp22 expression caused 40%
decrease in number of cells showing nuclear staining for p53
(Fig. 5C). Taken together, these data suggested that the inacti-
vation of p53 byDmHsp22 is not cell line-specific, and itmay be
responsible for proproliferative effects of DmHsp22 (delayed
aging of normal cells and increased malignant properties of
cancer cells) seen in human normal and cancer cells.
At the present time, there are no
known mammalian homologs of
DmHsp22. Whereas DmHsp22 is
localized in thematrix of mitochon-
dria in mammalian cells, the other
mammalian sHsps are mainly local-
ized in the cytosol and nucleus;
some cytosolic sHsps, for example
HspB2, have been reported to inter-
act with the outer membrane of the
mitochondria (40). In this regard,
DmHsp22 appears to be similar to
mammalianmtHsp70/mortalin and
Hsp60 that are found predomi-
nantly inmitochondria (41). Besides
the mitochondrial localization that
is observed formortalin, Hsp60, and
DmHsp22, they have molecular
chaperone function in vitro and in
vivo (15, 16, 42). Of note, whereas
mortalin and DmHsp22 caused life
span extension of normal human
cells, Hsp60 was not seen to have
such function in parallel assays, sug-
gesting that Dmhsp22 functions like
mortalin. The mechanism by which
it increases life span warrants fur-
ther studies. The cross-species ef-
fects would be of particular interest in understanding the
molecular mechanisms by which DmHsp22 regulates life span
and thus help to unveil the in vivo role of a mitochondrial small
Hsp.
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